Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorine 18 floretyrosine - Telix Pharmaceuticals

Next Previous
Drug Profile

Fluorine 18 floretyrosine - Telix Pharmaceuticals

Alternative Names: 18F-floretyrosine; 18F-FET; Floretyrosine (18F); Floretyrosine-F18; Fluorine-18-floretyrosine-Telix-Pharmaceuticals; O-(2-[18F]fluoroethyl)-L-tyrosine; Pixclara; Pixlumi; TLX 101-Cdx; TLX101 CDx; TLX101-Px

Latest Information Update: 25 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telix Pharmaceuticals
  • Class Amino acids; Antineoplastics; Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Glioma
  • Phase III Glioblastoma

Most Recent Events

  • 20 Aug 2026 The US FDA clears an IND application for phase III registrational trial for indication expansion in Brain metastases
  • 20 Aug 2026 Telix Pharmaceuticals plans a phase III registrational trial for Brain metastases
  • 22 Jul 2026 Telix Pharmaceuticals files an IND application with the FDA for phase III registrational trial for indication expansion in in Brain metastases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top